Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03912064 · MORE INFO

Limitations, agreements, and source contact

A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT · Source last updated 2026-01-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
point Of Contact
email
John_Koreth@dfci.harvard.edu
organization
Dana-Farber Cancer Institute
phone
617-632-3470
title
John Koreth, MD, PhD, MBBS
Complete source fields
certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
point Of Contact
email
John_Koreth@dfci.harvard.edu
organization
Dana-Farber Cancer Institute
phone
617-632-3470
title
John Koreth, MD, PhD, MBBS

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice